Novel cyclic biphalin analogue with improved antinociceptive properties

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Organic Chemistry

Background:

• Opioid peptides play crucial roles in pain modulation.
• Biphalin is a potent opioid peptide with mixed mu/delta receptor activity.
• Structural modifications of opioid peptides can alter their pharmacological profiles.

Purpose of the Study:

• To design and synthesize novel opioid analogues of biphalin.
• To investigate the impact of penicillamine substitutions on opioid receptor binding and activity.
• To elucidate the structure-activity relationships governing the differential pharmacological effects of the synthesized compounds.

Main Methods:

• Chemical synthesis of biphalin analogues incorporating d- or l-penicillamine.
• Disulfide bond formation to create cyclic opioid structures.
• In vitro receptor binding assays to determine affinities for mu and delta opioid receptors.
• In vivo antinociceptive assays to evaluate pain-relieving efficacy.
• Conformational analysis to explain observed pharmacological differences.

Main Results:

• Compound 9, featuring d-penicillamine, exhibited excellent mixed mu/delta opioid receptor affinities (Ki(δ) = 5.2 nM; Ki(μ) = 1.9 nM).
• Compound 9 demonstrated efficacious second messenger activation and potent in vivo antinociceptive activity.
• Compound 10, containing l-penicillamine, displayed significantly reduced pharmacological activity.
• Conformational studies provided an explanation for the distinct pharmacological profiles of compounds 9 and 10.

Conclusions:

• The stereochemistry of penicillamine residues critically influences the pharmacological activity of biphalin analogues.
• The d-penicillamine analogue (Compound 9) represents a promising lead for developing potent analgesics with mixed mu/delta receptor targeting.
• Conformational flexibility plays a key role in the differential binding and signaling of these novel opioid compounds.